

UK-based biotech firm raises \$45 M

07 July 2017 | News

The company plans to use the investment to complete clinical trials for their gene therapy products aimed at choroideremia, retinitis pigmentosa, and macular dystrophy.



London-based Nightstar, a company that develops treatments for retinal diseases, raised \$45 million in funding from several investors including Wellington Management Company, Redmile Group, Syncona, and New Enterprise Associates in a Series C financing round.

Nightstar is a biotechnology company that currently develops retinal gene therapy solutions for those with retinal dystrophies.

These are intended to be one-time treatments to prevent eventual blindness. Nightstar is currently researching and evaluating several gene therapy products.

The company plans to use the investment to complete clinical trials for their gene therapy products aimed at choroideremia, retinitis pigmentosa, and macular dystrophy.

Nightstar is building a pipeline of product candidates based on industry-leading gene therapy technology and ophthalmology expertise.